Acute benign positional vertigo. Benign paroxysmal vertigo
Conditions
Interventions
Intervention 1: Intervention group: Intramuscular promethazine 25 mg intramuscularly, single dose. Intervention 2: Intervention group: Intravenous ondansetron 4 mg single dose.
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: People aged between 18 and 65 years Having symptoms indicative of peripheral vertigo, including severe, paroxysmal vertigo, severe nausea and vomiting, with or without past or present auditory symptoms such as tinnitus or fullness in the ears Lack of new associated neurological symptoms
Exclusion criteria
Exclusion criteria: Drug allergy Lack of response to treatment within two hours after injection Having a drug reaction that leads to medical interventions and any type of severe complication, especially cardiac or cerebral events such as seizures, stroke, or cardiovascular disorders that threaten the patient's safety Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vertigo score based on VAS. Timepoint: vertigo score at the beginning of the study (before the intervention) and 1, 3, and 6 hours after drug injection. Method of measurement: based on Visual Analogue Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complications and patient satisfaction. Timepoint: at the beginning of the study. Method of measurement: Observation from the start of the intervention until 6 hours after drug injection. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mir Saeid Ramezani
Babol University of Medical Sciences
Outcome results
None listed